Follow-up Protocol to the Double-Blind Parts A and B of the Phase II Opsona Study OPN305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function)

Trial Profile

Follow-up Protocol to the Double-Blind Parts A and B of the Phase II Opsona Study OPN305-102 (A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody that Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jul 2017

At a glance

  • Drugs OPN 305 (Primary)
  • Indications Delayed graft function
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Opsona Therapeutics
  • Most Recent Events

    • 18 Nov 2016 This trial was completed in Germany (end date: 2016-06-06), according to European Clinical Trial Database.
    • 24 Sep 2016 This trial has been completed in Austria (Enda date:2016-06-06) according to European Clinical Trial Database.
    • 22 Sep 2016 This trial has been completed in Netherlands according to European Clinical Trial Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top